The aim of the current studies was to determine the effects of i) HGF neutralizing antibody AMG102, ii) a small molecule inhibitor for c-MET (Compound-A) and iii) the chemotherapeutic agent gemcitabine, alone or in dual and triple combinations on PC progression, using both in vivo and in vitro approaches. This evidence concerns the gene MET and pachyonychia congenita.